Trials / Completed
CompletedNCT01253213
BR55 in Prostate Cancer: an Exploratory Clinical Trial
Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- Male
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging. This will be compared with histopathology analysis (location based on expression of VEGFR2 in tissue specimens determined by immuno-histochemistry, IHC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BR55 | One to two bolus (2nd bolus optional) of BR55 per patient |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2010-12-03
- Last updated
- 2023-08-01
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01253213. Inclusion in this directory is not an endorsement.